Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Chemoradiotherapy in Early-Stage ENKTL
NCT04365036Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2020
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT), sponsored by Sun Yat-sen University. Started May 2020; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT04365036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365036.